The one-minute exercise that can slash your risk of heart disease
Technological advances and the habits of modern life have drastically reduced levels of physical activity around the world. The World Health Organisation (WHO) now warns that inactivity and sedentary lifestyles are one of the main risk factors for health problems and premature death.
It is important, however, to draw a distinction between a sedentary lifestyle and physical inactivity. Inactivity is defined as a level of daily movement below the healthy recommendations (a minimum of 30 minutes a day of moderate exercise). Sedentary refers to the hours of the day when we are sitting or lying down. This includes time spent commuting and at work, or at home reading, using a phone or watching TV.
Previously, people believed they just had to follow physical activity recommendations to stay healthy. However, research in recent years has shown that sedentary lifestyles can actually counteract the beneficial effects of regular physical activity.
Even if a person completes their recommended 30 minutes of daily physical activity or 7,000 steps, sitting for 8 hours or more each day is still considered sedentary. A study published in the journal PLoS ONE highlights that, while vigorous exercise can help mitigate some of the negative effects of sedentary lifestyles, reducing total time spent sitting is also essential.
Moreover, spending many hours sitting increases the overall risk of mortality by up to 40%, as highlighted by research published in the Journal of the American College of Cardiology.
Active breaks and 'exercise snacks'
Experts suggest that a good way to mitigate these risks is to take short breaks with movement throughout the day.
According to a 2021 study, so-called 'active breaks' or ' exercise snacks ' improve cardiometabolic capacity. In 2024, a review concluded that taking 3 to 4 minute high-intensity active breaks three times a day decreased the risk of cardiovascular disease and death from cancer. An even more recent article confirmed that they are a practical and feasible way to improve cardiovascular fitness, metabolic capacity and muscle function.
What kind of exercise is best?
Until recently, it was not actually clear which type of exercise works best in this context. To answer this question, a recent study in the journal Medicine & Science in Sports compared the effectiveness of various activities for glucose control in overweight young men.
The researchers divided volunteers into four groups: one group sat for 8 hours or more a day; another group took a 30-minute walking break; the third group went for a 3-minute walk every 45 minutes; and the fourth group did 10 squats every 45 minutes.
They concluded that performing 10 squats or walking for 3 minutes every 45 minutes is more effective than walking for half an hour at a time in managing blood sugar levels.
An accessible solution
It is crucial to adopt more active lifestyle habits to mitigate the risks of a sedentary lifestyle. While the World Health Organisation recommends at least 150 minutes of moderate physical activity per week, it is also important to incorporate exercise and some strength work.
But if this is not possible, then incorporate moderate to high intensity exercise snacks at home or in the office. Active breaks of 1 to 3 minutes every 45 minutes or every hour are sufficient.
And in addition to the 10 squats, there are other alternatives, depending on each person's preferences: climbing stairs, taking short walks, jumping in place or even walking with long strides. Remember that these small daily doses of effort have great health benefits, improving cardiovascular function, metabolic capacity and muscle function.
Beatriz Carpallo Porcar and Rita Galán Díaz are physiotherapists who are part of the teaching and research staff in physiotherapy at San Jorge University.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
an hour ago
- BBC News
NHS plans to DNA test all babies in England to assess disease risk
Every newborn baby in England will have their DNA mapped to assess their risk of hundreds of diseases, under NHS plans for the next 10 scheme, first reported by the Daily Telegraph, is part of a government drive towards predicting and preventing illness, which will also see £650m invested in DNA research for all patients by Secretary Wes Streeting said gene technology would enable the health service to "leapfrog disease, so we're in front of it rather than reacting to it".It comes after a study analysing the genetic code of up to 100,000 babies was announced in October. The government's 10-year plan for the NHS, which is set to be revealed over the next few weeks is aimed at easing pressure on Department for Health and Social Care said that genomics - the study of genes - and AI would be used to "revolutionise prevention" and provide faster diagnoses and an "early warning signal for disease".Screening newborn babies for rare diseases will involve sequencing their complete DNA using blood samples from their umbilical are approximately 7,000 single gene disorders. The NHS study which began in October only looked for gene disorders that develop in early childhood and for which there are effective newborn babies are only given a heelprick blood test that checks for nine serious conditions, including cystic health secretary said in a statement: "With the power of this new technology, patients will be able to receive personalised healthcare to prevent ill-health before symptoms begin, reducing the pressure on NHS services and helping people live longer, healthier lives."
The Independent
5 hours ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
The Independent
7 hours ago
- The Independent
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association 's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
